Loading…
Employees: 251
Size CellaVision (CEVI.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $485M, the 179th largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 199.00 on 6 Nov 2026.
Performance Over six months the shares gained 67.8%, against -14.2% for the median peer and +8.2% for the Sweden market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 1.9% over the last twelve months (peer median +1.2%); the operating margin is 23.0% (peer median 4.4%).
Valuation It trades at 31.8× forward earnings against a peer median of 14.1× (3rd most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 12.2 points above its cost of capital (5.9% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 763M | SEK 759M | SEK 723M | SEK 677M | SEK 639M |
| Revenue growth | — | +5% | +7% | +6% | — |
| Gross profit | SEK 519M | SEK 495M | SEK 463M | SEK 440M | SEK 413M |
| EBITDA | SEK 222M | SEK 241M | SEK 219M | SEK 207M | SEK 202M |
| Net income | SEK 138M | SEK 153M | SEK 141M | SEK 130M | SEK 118M |
| Free cash flow | SEK 182M | SEK 182M | SEK 186M | SEK 165M | SEK 114M |
| Capital expenditure | SEK 86.2M | SEK 86.3M | SEK 77.7M | SEK 86.5M | SEK 69.4M |
| Total debt | SEK 49.8M | SEK 25.7M | SEK 26.8M | SEK 64.7M | SEK 102M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CEVI.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +20.5% | -6.9% | 3rd highest of 21 |
| 6-month return | +67.8% | -14.2% | 2nd highest of 21 |
| Distance from 52-week high | -2.5% | -35.1% | highest of 21 |
| Revenue growth (TTM) | +1.9% | +1.2% | 10th highest of 21 |
| Operating margin | 23.0% | 4.4% | 2nd highest of 21 |
| Forward P/E | 31.8× | 14.1× | 3rd most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 6.5% | 11.5% | 5th least demanding of 14 |
| Growth delivered (Del g) | +10.0% | +0.4% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -3.5 pp | +6.6 pp | 4th least demanding of 14 |
| ROIC minus cost of capital | +12.2 pp | -3.8 pp | 2nd highest of 19 |
| EV / EBITDA | 20.6× | 9.2× | 2nd most expensive of 4 |
| Net debt / EBITDA | -0.8× | -0.7× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 31.8× | 6.5% | +10.0% |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 12.2× | -5.6% | +7.7% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 59.1× | 11.5% | +11.0% |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | n/a | 35.5% | -6.9% |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | 6.7× | n/a | n/a |
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | n/a | n/a | n/a |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 12.2× | n/a | n/a |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 18.5× | 19.3% | +12.4% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | n/a | 3.8% | -2.8% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | n/a | 22.2% | -11.7% |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | n/a | 6.7% | +0.3% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 38.6× | 22.1% | +2.2% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | n/a | 42.6% | +0.4% |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | n/a | n/a | n/a |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | n/a | n/a | n/a |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 23.6× | n/a | n/a |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | n/a | 10.1% | +120.2% |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 27% | 14.1× | 0.9% | +15.6% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | n/a | 14.8% | -4.7% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 7.4× | -3.9% | -4.3% |